Cargando…

Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes

Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS...

Descripción completa

Detalles Bibliográficos
Autores principales: Schön, Martin, Zaharia, Oana P., Strassburger, Klaus, Kupriyanova, Yuliya, Bódis, Kálmán, Heilmann, Geronimo, Strom, Alexander, Bönhof, Gidon J., Michelotti, Filippo, Yurchenko, Iryna, Möser, Clara, Huttasch, Maximilian, Bombrich, Maria, Kelm, Malte, Burkart, Volker, Schrauwen-Hinderling, Vera B., Wagner, Robert, Roden, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545555/
https://www.ncbi.nlm.nih.gov/pubmed/37478166
http://dx.doi.org/10.2337/db23-0353
_version_ 1785114694174900224
author Schön, Martin
Zaharia, Oana P.
Strassburger, Klaus
Kupriyanova, Yuliya
Bódis, Kálmán
Heilmann, Geronimo
Strom, Alexander
Bönhof, Gidon J.
Michelotti, Filippo
Yurchenko, Iryna
Möser, Clara
Huttasch, Maximilian
Bombrich, Maria
Kelm, Malte
Burkart, Volker
Schrauwen-Hinderling, Vera B.
Wagner, Robert
Roden, Michael
author_facet Schön, Martin
Zaharia, Oana P.
Strassburger, Klaus
Kupriyanova, Yuliya
Bódis, Kálmán
Heilmann, Geronimo
Strom, Alexander
Bönhof, Gidon J.
Michelotti, Filippo
Yurchenko, Iryna
Möser, Clara
Huttasch, Maximilian
Bombrich, Maria
Kelm, Malte
Burkart, Volker
Schrauwen-Hinderling, Vera B.
Wagner, Robert
Roden, Michael
author_sort Schön, Martin
collection PubMed
description Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent (1)H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO(2)max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ∼30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ∼36% and ∼62% lower compared with type 1 diabetes and control subjects, respectively. After 5 years, the M-value decreased by ∼29% in type 1 and ∼13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO(2)max. IMCL also associated with microalbuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications. ARTICLE HIGHLIGHTS: Intramyocellular lipid content (IMCL) can be elevated in insulin-resistant humans, but its dynamics and association with comorbidities remain unclear. Independently of age, sex, body mass, and skeletal muscle volume, IMCL is higher in recent-onset type 2, but not type 1 diabetes, and remains unchanged within 5 years, despite worsening insulin resistance. A degree of physical fitness modulates the association between IMCL and insulin sensitivity in type 2 diabetes. Whereas higher IMCL associates with lower insulin sensitivity in people with lower physical fitness, there is no association between IMCL and insulin sensitivity in those with higher degree of physical fitness. IMCL associates with progression of microalbuminuria, cardiovascular disease risk, and cardiac autonomic neuropathy.
format Online
Article
Text
id pubmed-10545555
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-105455552023-10-04 Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes Schön, Martin Zaharia, Oana P. Strassburger, Klaus Kupriyanova, Yuliya Bódis, Kálmán Heilmann, Geronimo Strom, Alexander Bönhof, Gidon J. Michelotti, Filippo Yurchenko, Iryna Möser, Clara Huttasch, Maximilian Bombrich, Maria Kelm, Malte Burkart, Volker Schrauwen-Hinderling, Vera B. Wagner, Robert Roden, Michael Diabetes Pathophysiology Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent (1)H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO(2)max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ∼30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ∼36% and ∼62% lower compared with type 1 diabetes and control subjects, respectively. After 5 years, the M-value decreased by ∼29% in type 1 and ∼13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO(2)max. IMCL also associated with microalbuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications. ARTICLE HIGHLIGHTS: Intramyocellular lipid content (IMCL) can be elevated in insulin-resistant humans, but its dynamics and association with comorbidities remain unclear. Independently of age, sex, body mass, and skeletal muscle volume, IMCL is higher in recent-onset type 2, but not type 1 diabetes, and remains unchanged within 5 years, despite worsening insulin resistance. A degree of physical fitness modulates the association between IMCL and insulin sensitivity in type 2 diabetes. Whereas higher IMCL associates with lower insulin sensitivity in people with lower physical fitness, there is no association between IMCL and insulin sensitivity in those with higher degree of physical fitness. IMCL associates with progression of microalbuminuria, cardiovascular disease risk, and cardiac autonomic neuropathy. American Diabetes Association 2023-10 2023-07-21 /pmc/articles/PMC10545555/ /pubmed/37478166 http://dx.doi.org/10.2337/db23-0353 Text en © 2023 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
spellingShingle Pathophysiology
Schön, Martin
Zaharia, Oana P.
Strassburger, Klaus
Kupriyanova, Yuliya
Bódis, Kálmán
Heilmann, Geronimo
Strom, Alexander
Bönhof, Gidon J.
Michelotti, Filippo
Yurchenko, Iryna
Möser, Clara
Huttasch, Maximilian
Bombrich, Maria
Kelm, Malte
Burkart, Volker
Schrauwen-Hinderling, Vera B.
Wagner, Robert
Roden, Michael
Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
title Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
title_full Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
title_fullStr Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
title_full_unstemmed Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
title_short Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes
title_sort intramyocellular triglyceride content during the early course of type 1 and type 2 diabetes
topic Pathophysiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545555/
https://www.ncbi.nlm.nih.gov/pubmed/37478166
http://dx.doi.org/10.2337/db23-0353
work_keys_str_mv AT schonmartin intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT zahariaoanap intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT strassburgerklaus intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT kupriyanovayuliya intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT bodiskalman intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT heilmanngeronimo intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT stromalexander intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT bonhofgidonj intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT michelottifilippo intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT yurchenkoiryna intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT moserclara intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT huttaschmaximilian intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT bombrichmaria intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT kelmmalte intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT burkartvolker intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT schrauwenhinderlingverab intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT wagnerrobert intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT rodenmichael intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes
AT intramyocellulartriglyceridecontentduringtheearlycourseoftype1andtype2diabetes